HLA-E and non-small cell lung carcinoma: However, when overall survival was recorded during follow-up, no significant differences were observed in relation to ATB treatment, TMB, and HLA-E type, suggesting that these factors only influence PFS during a relatively short period of time in these advanced NSCLC patients (Figure S1).